Menu
Back to Journals » Breast Cancer: Targets and Therapy » Volume 5
Emerging targeted combinations in the management of breast cancer
Authors Lee, Armstrong, Wardley A
Received 20 December 2012
Accepted for publication 4 March 2013
Published 13 August 2013 Volume 2013:5 Pages 61—72
DOI https://doi.org/10.2147/BCTT.S26771
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Rebecca J Lee, Anne C Armstrong, Andrew M Wardley
Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK
Abstract: The number of targeted treatments has risen exponentially over the last few years and is an important concept in the fight against cancer. This review will concentrate on some of the main treatments targeting aberrant pathways which have been tested mainly in the Phase I/II setting. These include human epidermal growth factor receptor 2 inhibitors, drug-antibody conjugates, epidermal growth factor receptor inhibitors, vascular endothelial growth factor inhibitors, reticular activating system, mammalian target of rapamycin and multi-kinase inhibitors. Further knowledge of these pathways and the predictors of response to them will enable personalized medicine to become a reality.
Keywords: breast cancer, targeted therapy, tyrosine kinase, receptor
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.